Among them, the trial NCT04592874 aims to evaluate the safety, tolerability, and efficacy of AL002, a monoclonal antibody targeting TREM2 in patients with early AD, with the goal of enhancing microglial function to reduce neuroinflammation and possibly slow disease progression [118]. This evidence concerns the gene TREM2 and Alzheimer disease.